Mogrify is a company that focuses on cell reprogramming technology. Mogrify develops platforms for enhanced forward programming or transdifferentiation of cell types, leveraging epigenetic data to identify optimal combinations of transcription factors or growth factors for cell reprogramming.

Mogrify

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). 

The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.

Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.

Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.

Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

Taking a moment to celebrate Professor Jose Maria Polo, Mogrify Founder and Director of the University of Adelaide Centre for Epigenetics, who was recently recognised for his cutting edge research in the fields of #epigenetics and #cellularreprogramming with election into the Australian Academy of Science Fellowship.

Today we are thrilled to announce the appointment of Dr Jonathan Appleby as Chief Scientific Officer. With decades of industry experience in translating both conventional and advanced therapeutic medicines, Jon will lead advancement of our in vivo reprogramming therapy programs in areas including otology, ophthalmology and diabetes toward and into clinical development.

Dr Appleby is an accomplished medicines developer, having operated in all phases of therapeutic development from discovery to commercial launch. He joins Mogrify from the Cell and Gene Therapy Catapult, where he was Executive Director and Chief Scientific Officer and led the R&D group focused on ATMP manufacturing processes and analytical development for five years. Prior to this, Dr Appleby was CSO for Cell and Gene Therapy in GSK’s Rare Diseases Unit, where he led the team that developed Strimvelis, the multi-award-winning and first autologous pediatric CD34+ stem cell gene therapy to be approved for commercial use. He also led for 2 years the ARSA gene therapy, which was later out-licensed to Orchard Therapeutics and recently approved as Lenmeldy.

Read the press release:
https://lnkd.in/eMPFjk_X

Mogrify CEO, Dr Darrin M Disley OBE, recently sat down with Singular: Building Brilliant Biotechs to discuss the state of the market and the fundamentals of biotech and life science investment.

The corneal epithelium acts as a barrier to pathogens entering the eye; corneal epithelial cells are continuously renewed by uni-potent, quiescent limbal stem cells (LSCs) located at the limbus, where the cornea transitions to the conjunctiva. There has yet to be a consensus on LSC markers and their transcriptome profile is not fully understood, which may be due to using cadaveric tissue without an intact stem cell niche for transcriptomic.

In a recently published study, members of the Mogrify team addressed this problem by using single nuclei RNA sequencing (snRNAseq) on healthy human limbal tissue that was immediately snap-frozen after excision from patients undergoing cataract surgery. snRNAseq has previously been used to resolve the cellular heterogeneity and transcriptional profiles of several frozen tissues and organs, so it was subsequently used here to define the transcriptomes of the cell sub-populations within the human limbus.

Read the full article: 
https://lnkd.in/esZXfk6W

🗣 Thrilled to announce my participation as a speaker at the upcoming Life Sciences Patent Network (LSPN) Europe conference in London on 21 November.

💡  I'll be on a panel discussing "Fully exploiting your innovations: best practice in invention harvesting and managing collaborative IP". This will include references to Mogrify’s proprietary platform technologies enabling systematic control of human cell fate and underpinning Mogrify’s pipeline of novel in vivo reprogramming therapies.

✳ Plenty of other interesting agenda items on the latest trends and strategies in the dynamic world of life sciences IP.

👋 Hope to see you at #LSPNEurope 

https://bit.ly/3rZ5aCZ
#LSPNEurope #SpeakerAnnouncement #LifeSciencesIP #Innovation #Networking #Mogrify

Only 3-weeks until we’ll be joining many of the biopharma community at the Biotechnology Innovation Organization's International Convention 2024, June 3-6, in San Diego. 

Connect with Mogrify CEO, Dr Darrin M Disley OBE, who will be on hand to navigate you through the latest from the MOGRIFY® direct #cellreprogramming technology and its deployment in the translation of novel in vivo reprogramming therapies for otology, ophthalmology, and other areas of degenerative disease.

Find us through BIO One-on-one Partnering or reach out directly via the link:
https://lnkd.in/gxeg3vVz

UK:CO:MOGRIFY

Mogrify